Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company is headquartered in Irvine, California.
| Revenue (TTM) | $74.64M |
| Gross Profit (TTM) | $20.73M |
| EBITDA | $12.11M |
| Operating Margin | 15.50% |
| Return on Equity | 29.80% |
| Return on Assets | 9.70% |
| Revenue/Share (TTM) | $23.01 |
| Book Value | $14.14 |
| Price-to-Book | 4.37 |
| Price-to-Sales (TTM) | 2.52 |
| EV/Revenue | 2.757 |
| EV/EBITDA | 11.33 |
| Quarterly Earnings Growth (YoY) | 22.40% |
| Quarterly Revenue Growth (YoY) | 14.60% |
| Shares Outstanding | $3.19M |
| Float | $1.75M |
| % Insiders | 36.46% |
| % Institutions | 32.41% |
Volatility is currently expanding
Pro-Dex reported nice Q1 sales of $19.9 million, which is up 14.6% YoY. Their largest customer contract now runs through December 2028, reducing potential near-term risks in that sense. Also, their APM acquisition gives them more control over their supply chain and brings some potential aerospace/defense optionality.
IRVINE, CA / ACCESS Newswire / April 30, 2026 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2026 third quarter ended March 31, 2026.
